COGNITION: a prospective precision oncology trial for patients with early breast cancer at high risk following neoadjuvant chemotherapy
Constantin Pixberg, Marc Zapatka, Mario Hlevnjak, S. Benedetto, Jan-Philip Suppelna, Joerg Heil, Katharina Smetanay, Laura L. Michel, Carlo Fremd, V. Körber, Marc Rübsam, Lars Buschhorn, Sabine Heublein, Benedikt Schäfgen, Michael Golatta, Christina Gomez, Alexandra von Au, Markus Wallwiener, Stephan Wolf, Nicola Dikow, Christian P. Schaaf, E. Gutjahr, Michael Allgäuer, Albrecht Stenzinger, Katrin Pfütze, Romy Kirsten, Daniel Hübschmann, Hans‐Peter Sinn, D. Jäger, A. Trumpp, Richard F. Schlenk, Timothy J Hofer, Verena Thewes, Andreas Schneeweiß, Peter Lichter
Abstract
BACKGROUND: COGNITION (Comprehensive assessment of clinical features, genomics and further molecular markers to identify patients with early breast cancer for enrolment on marker driven trials) is a diagnostic registry trial that employs genomic and transcriptomic profiling to identify biomarkers in patients with early breast cancer with a high risk for relapse after standard neoadjuvant chemotherapy (NACT) to guide genomics-driven targeted post-neoadjuvant therapy. PATIENTS AND METHODS: At National Center for Tumor Diseases Heidelberg patients were biopsied before starting NACT, and for patients with residual tumors after NACT additional biopsy material was collected. Whole-genome/exome and transcriptome sequencing were applied on tumor and corresponding blood samples. RESULTS: In the pilot phase 255 patients were enrolled, among which 213 were assessable: thereof 48.8% were identified to be at a high risk for relapse following NACT; 86.4% of 81 patients discussed in the molecular tumor board were eligible for a targeted therapy within the interventional multiarm phase II trial COGNITION-GUIDE (Genomics-guided targeted post neoadjuvant therapy in patients with early breast cancer) starting enrolment in Q4/2022. An in-depth longitudinal analysis at baseline and in residual tumor tissue of 16 patients revealed some cases with clonal evolution but largely stable genetic alterations, suggesting restricted selective pressure of broad-acting cytotoxic neoadjuvant chemotherapies. CONCLUSIONS: While most precision oncology initiatives focus on metastatic disease, the presented concept offers the opportunity to empower novel therapy options for patients with high-risk early breast cancer in the post-neoadjuvant setting within a biomarker-driven trial and provides the basis to test the value of precision oncology in a curative setting with the overarching goal to increase cure rates.